Please assess the completion status of the following clinical trial:

Trial Title: Medrol Dosepak Taper for Delayed Post-op Recovery After TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient undergoing primary TKA with a diagnosis of osteoarthritis~* ≥ 18 years old~* ROM \<90° by 3 weeks postoperatively without improvement to \>90° by 6 weeks~* Requiring a 30-pill oxycodone refill~* NSAID allergy~* Thigh circumference discrepancy \>2cm between legs from 3 to 6 weeks~* Defense and Veterans Pain Rating Scale (DVPRS) \> 5 between 3 and 6 weeks~* Willingness to undergo randomization~Exclusion Criteria:~* Reported chronic corticosteroid or opiate use~* Suspected or confirmed periprosthetic joint infection~* Revision TKA~* Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, or post-traumatic arthritis~* American Society of Anesthesiologists (ASA) score ≥ 4~* Reported history of liver or renal disease~* Uncontrolled diabetes~* Immunosuppression~* ≤ 18 years old~* Inability to take oral medications~* Unable to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Methylprednisolone taper (Type: ACTIVE_COMPARATOR): 21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM \<90° at 8 weeks
- Placebo taper (Type: PLACEBO_COMPARATOR): 21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).